MASH Updates: Sagimet, Altimmune, GSK Discuss Development Plans At AASLD

 
• By Joseph Haas
  
AASLD 2025 - The Liver Meeting
Multiple companies provided updates on their MASH R&D plans at AASLD 2025 (Joseph Haas/Citeline)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business